JP2021532832A5 - - Google Patents
Info
- Publication number
- JP2021532832A5 JP2021532832A5 JP2021529256A JP2021529256A JP2021532832A5 JP 2021532832 A5 JP2021532832 A5 JP 2021532832A5 JP 2021529256 A JP2021529256 A JP 2021529256A JP 2021529256 A JP2021529256 A JP 2021529256A JP 2021532832 A5 JP2021532832 A5 JP 2021532832A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- oligonucleotide
- transferrin receptor
- complex
- fxn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714035P | 2018-08-02 | 2018-08-02 | |
| US62/714,035 | 2018-08-02 | ||
| PCT/US2019/044959 WO2020028840A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021532832A JP2021532832A (ja) | 2021-12-02 |
| JP2021532832A5 true JP2021532832A5 (enExample) | 2022-08-10 |
Family
ID=69232074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529256A Pending JP2021532832A (ja) | 2018-08-02 | 2019-08-02 | フリートライヒ運動失調症を処置するための筋標的化複合体およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210308274A1 (enExample) |
| EP (1) | EP3830131A4 (enExample) |
| JP (1) | JP2021532832A (enExample) |
| KR (1) | KR20210086601A (enExample) |
| CN (1) | CN113166240A (enExample) |
| CA (1) | CA3108386A1 (enExample) |
| EA (1) | EA202190419A1 (enExample) |
| IL (1) | IL280535A (enExample) |
| WO (1) | WO2020028840A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| KR20230117182A (ko) | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| CA3222816A1 (en) * | 2021-06-21 | 2022-12-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2023371614A1 (en) * | 2022-11-04 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| US12527877B2 (en) | 2024-01-24 | 2026-01-20 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
| WO2026136804A1 (en) | 2024-12-20 | 2026-06-25 | Denali Therapeutics Inc. | Compositions and methods for modulating synuclein expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015023939A1 (en) * | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin |
| CA2921457A1 (en) * | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Heterochromatin forming non-coding rnas |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| US20190002876A1 (en) * | 2014-12-09 | 2019-01-03 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treatment of friedreich's ataxia |
| SG10201912763QA (en) * | 2015-11-05 | 2020-02-27 | Bamboo Therapeutics Inc | Modified friedreich ataxia genes and vectors for gene therapy |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| AU2019315593B2 (en) * | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
-
2019
- 2019-08-02 CA CA3108386A patent/CA3108386A1/en active Pending
- 2019-08-02 CN CN201980064588.8A patent/CN113166240A/zh active Pending
- 2019-08-02 KR KR1020217006029A patent/KR20210086601A/ko not_active Withdrawn
- 2019-08-02 JP JP2021529256A patent/JP2021532832A/ja active Pending
- 2019-08-02 EA EA202190419A patent/EA202190419A1/ru unknown
- 2019-08-02 EP EP19845433.2A patent/EP3830131A4/en active Pending
- 2019-08-02 WO PCT/US2019/044959 patent/WO2020028840A1/en not_active Ceased
- 2019-08-02 US US17/265,019 patent/US20210308274A1/en not_active Abandoned
-
2021
- 2021-01-31 IL IL280535A patent/IL280535A/en unknown